Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PBLS with free AI briefings, catalyst countdowns, and dilution alerts.

PBLS · Parabilis Medicines, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1B Cash on Hand
128.7mo Cash Runway
Follow PBLS by email Get an email when PBLS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PBLS, unsubscribe in one click. Privacy

📣 What PBLS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Zolucatetide (FOG-001) Cancer Phase 1/2 · NCT05919264 Recruiting
Fluorouracil Cancer Phase 1/2 · NCT05919264 Recruiting
Trifluridine and Tipiracil Hydrochloride Cancer Phase 1/2 · NCT05919264 Recruiting

Also used in these trials (approved or third-party drugs, not PBLS's own candidates): Bevacizumab, Nivolumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PBLS holds $1.1B in cash and short-term investments (as of Jun 30, 2026) and burns about $26.1M/quarter from operations, an estimated runway of 128.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PBLS files for a raise →

Get the full PBLS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBLS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.